Clostridium difficile infections elevate the risks for colectomy, mortality and postoperative complications after a colectomy for patients with ulcerative colitis, according to NEJM Journal Watch.

Risk for Clostridioides difficile (C. diff) infection wasn't any greater with vedolizumab (Entyvio) versus anti-tumor necrosis factor (TNF) agents for ulcerative colitis, a researcher reported. In a ...

In a phase-one human clinical trial, a pharmacist researcher has demonstrated that a new antibiotic, called Omadacycline, may be a promising tool in combating the superbug known as C diff which causes ...

Q: I'm not sure you'll take this question because of the subject matter, but it seems pretty important. Our dad had a fecal transplant as a last-ditch treatment for C. diff (Clostridioides difficile), ...

Iron storage “spheres” inside the bacterium C. diff — the leading cause of hospital-acquired infections — could offer new targets for antibacterial drugs to combat the pathogen. A team of Vanderbilt ...

Newly discovered iron storage 'ferrosomes' inside the bacterium C. diff -- the leading cause of hospital-acquired infections -- are important for infection in an animal model and could offer new ...

An inflammation of the colon associated with C. difficile — C. difficile colitis — has increased nearly 50 percent from 2001-2005 to 2006-2010, according to a study in the Journal of the American ...

Kevin Garey, University of Houston Robert L. Boblitt Endowed Professor of Drug Discovery at the UH College of Pharmacy, assessed the pharmacokinetics and gut microbiome effects of oral Omadacycline in ...

Prompt treatment with fecal transplant can improve survival among critically ill C. difficile patients 14 of 18 patients with life-threatening C. diff survived after a fecal transplant Antibiotics ...

A fecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multi-drug resistant organisms both in the ...

Scientists in Pennsylvania have developed an experimental mRNA-based vaccine for C. diff bacteria, which often cause recurring, miserable bouts of diarrhea. Reading time 3 minutes We might soon have a ...